RYTM Q2 2025 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M+66.8% YoY

Gross Profit

$43M88.6% margin

Operating Income

-$45M-93.4% margin

Net Income

-$47M-96.1% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

+48.3%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$373M

Total Liabilities

$385M

Stockholders' Equity

-$12M

Cash & Equivalents

$136M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$29M	+66.8%
Gross Profit	$43M	$26M	+64.4%
Operating Income	-$45M	-$40M	-11.9%
Net Income	-$47M	-$32M	-44.5%

Revenue Segments

Product

$49M100%

Geographic Segments

Non-US

$17M100%